JRI's NAV continues to rise in early 2026, supported by strong real asset exposure and a diversified portfolio across equities and debt. Read why JRI is a Buy.
Abbott Laboratories just paid its quarterly dividend of $0.63 per share on February 13, 2026, marking a 6.8% increase from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results